Type(s) of breast cancer-Breast carcinoma Posts on Medivizor
Navigation Menu

Type(s) of breast cancer-Breast carcinoma Posts on Medivizor

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Posted by on Sep 6, 2020 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...

Read More

Searching for patients with advanced breast cancer to trial an experimental drug combination

Searching for patients with advanced breast cancer to trial an experimental drug combination

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...

Read More

Differential effects of docetaxel-based chemotherapy according to body mass in patients with early breast cancer

Differential effects of docetaxel-based chemotherapy according to body mass in patients with early breast cancer

Posted by on Aug 9, 2020 in Breast cancer | 0 comments

In a nutshell The study investigated whether chemotherapy after surgery with or without docetaxel (Taxotere) has different outcomes in patients with different body mass indexes (BMI; a measurement of body weight in relation to height) and early breast cancer (BC). The main finding was that patients responded differently to docetaxel based on...

Read More

Palbociclib and exemestane versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer

Posted by on Dec 7, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.  This study concluded that palbociclib and endocrine therapy is more effective than...

Read More

Side effects of ado-trastuzumab emtansine impacting outcomes in patients with HER2+ advanced breast cancer

Posted by on Aug 25, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer.  This study concluded that these side effects do not impact the outcomes for these patients.   Some background...

Read More

Searching for patients with triple negative breast cancer to test durvalumab and olaparib

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...

Read More

Searching for patients with early stage breast cancer to trial a new radiation treatment plan

Posted by on Mar 27, 2019 in Breast cancer | 0 comments

In a nutshell The trial aims to investigate a new way of delivering radiation therapy in women with early-stage breast cancer. This will involve low doses of radiation therapy being aimed at the part of the breast where the tumor is or was. The main outcomes that will be measured are side effects and recurrence rate. This trial is recruiting in Missouri,...

Read More